BRPI9915552B8 - pirimidinas inibidoras da reprodução do hiv - Google Patents

pirimidinas inibidoras da reprodução do hiv

Info

Publication number
BRPI9915552B8
BRPI9915552B8 BRPI9915552A BR9915552A BRPI9915552B8 BR PI9915552 B8 BRPI9915552 B8 BR PI9915552B8 BR PI9915552 A BRPI9915552 A BR PI9915552A BR 9915552 A BR9915552 A BR 9915552A BR PI9915552 B8 BRPI9915552 B8 BR PI9915552B8
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
nhc
amino
alkyloxycarbonyl
Prior art date
Application number
BRPI9915552A
Other languages
English (en)
Other versions
BR9915552B1 (pt
BR9915552A (pt
Inventor
De Corte Bart
Yung Ho Chih
William Ludovici Donald
Heeres Jan
Jeanne Alfons Vans Aken Koen
Jozef Lodenwijk Marcel Andries Koenraad
Maria Henricus Koymans Lucien
Rene De Jonge Marc
Joseph Kukla Michael
Adriaan Jan Janssen Paul
W Kavash Robert
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9915552(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9915552A publication Critical patent/BR9915552A/pt
Publication of BR9915552B1 publication Critical patent/BR9915552B1/pt
Publication of BRPI9915552B8 publication Critical patent/BRPI9915552B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

patente de invenção: <b>"pirimidinas inibidoras da reprodução do hiv"<d>. esta invenção trata do uso de compostos da fórmula (i), os n-óxidos, os sais de adição farmaceuticamente aceitáveis, aminas qua-ternárias e a sua forma estereoquimicamente isoméricas, onde a^ 1^=a^ 2^=a^ 3^=a^ 4^-forma um fenila, piridinila, pirimidinila, piridazinila ou pirazinila com o grupo vinila agregado; n é 0 a 4; e onde possível 5; r^ 1^ é hidrogênio, arila, formila, c~ 1-6~alquilcarbonila, c~ 1-6~alquila, c~ 1-6~alquiloxicarbonila, c~ 1-6~ alquila substituída ou c~ 1-6~alquilóxic~ 1-6~ alquilcarbonila substituída; cada r3 independentemente é hidróxi, halo, opcionalmente substituído c~ 1-6~ alquila, c~ 2-6~alquenila ou c~ 2-6~-alquinila, c~ 3-7~cicloalquila, c~ 1-6~alquilóxi, c~ 1-6~alquiloxicarbonila, carboxila, ciano, nitro, amino, mono- ou di(c~ 1-6~alquila)amino, polihalometila, polihalo-metilóxi, polihalometiltio, -s(=o)~ p~r^ 6^, -nh-s(=o)~ p~r^ 6^, - c(=o)r^ 6^, -nhc(=o)h, -c(=o)nhnh~ 2~, -nhc(=o)r^ 6^, -c(=nh)r^ 6^ ou um anel heterocíclico de 5 membros; p é 1 ou 2; l é opcionalmente substituído c~ 1-10~ alquila, c~ 2-10~ alquenila ou c~ 3-7~ cicloalquila; ou l é -x-r^ 3^ onde r^ 3^ é fenila, piridinila, pirimidinila, pirazinila ou piridazinila, opcionalmente substituída x é -nr^ 1^-, -nh-nh-, -n=n, -o-, c(=o)-choh-, -s-, -s(=o)- ou -s(=o)~ 2~-; q é hidrogênio, c~ 1-6~alquila, halo, polihalo-c~ 1-6~alquila ou um grupo opcionalmente substituído; y representa hidróxi, halo c~ 3-7~cicloalquila, c~ 1-6~alquila, c~ 2-6~ alquenila ou c~ 2-6~ alquila, opcionalmente substituída, c~ 1-6~alquilóxi, c~ 1-6~ alquiloxicarbonila, carbonila, ciano, nitro, amino, mono-ou di(c~ 1-6~ alquila)amino, polihalo-metila, polihalometilóxi, polihalometitio, -s(=o)~ p~r^ 6^, -nh-s(=o)~ p~r^ 6^, -c(=o)r^ 6^, -nhc(=o)h, -c(=o)nhnh~ 2~, -nhc(=o)r^ 6^, -c(=nh)r^ 6^ ou arila; arila é fenila opcionalmente substituído; het é um radical heterocíclico opcionalmente substituída; para a fabricação de um medicamento para o tratamento de doentes sofrendo da infecção do hiv (vírus da imunodeficiência humana).
BRPI9915552A 1998-11-10 1999-09-24 pirimidinas inibidoras da reprodução do hiv BRPI9915552B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (3)

Publication Number Publication Date
BR9915552A BR9915552A (pt) 2001-08-14
BR9915552B1 BR9915552B1 (pt) 2013-11-19
BRPI9915552B8 true BRPI9915552B8 (pt) 2021-05-25

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915552A BRPI9915552B8 (pt) 1998-11-10 1999-09-24 pirimidinas inibidoras da reprodução do hiv

Country Status (41)

Country Link
US (5) US6878717B2 (pt)
EP (2) EP1270560B1 (pt)
JP (1) JP3635238B2 (pt)
KR (1) KR100658489B1 (pt)
CN (1) CN1214013C (pt)
AP (1) AP1683A (pt)
AR (1) AR024227A1 (pt)
AT (2) ATE233740T1 (pt)
AU (2) AU762523C (pt)
BG (1) BG65103B1 (pt)
BR (1) BRPI9915552B8 (pt)
CA (1) CA2350801C (pt)
CY (1) CY2008021I1 (pt)
CZ (1) CZ301367B6 (pt)
DE (3) DE69905683T2 (pt)
DK (1) DK1002795T3 (pt)
EA (1) EA004049B1 (pt)
EE (1) EE05086B1 (pt)
ES (2) ES2193664T3 (pt)
FR (1) FR09C0004I2 (pt)
HK (1) HK1048817B (pt)
HR (2) HRP20080359B1 (pt)
HU (2) HU227453B1 (pt)
ID (1) ID28376A (pt)
IL (2) IL143023A0 (pt)
LT (1) LTC1002795I2 (pt)
LU (1) LU91528I2 (pt)
MY (1) MY121108A (pt)
NL (1) NL300373I2 (pt)
NO (3) NO318801B1 (pt)
NZ (1) NZ511116A (pt)
OA (1) OA11674A (pt)
PL (1) PL204427B1 (pt)
PT (1) PT1002795E (pt)
SI (1) SI1002795T1 (pt)
SK (2) SK287270B6 (pt)
TR (1) TR200101306T2 (pt)
TW (1) TWI238161B (pt)
UA (1) UA70966C2 (pt)
WO (1) WO2000027825A1 (pt)
ZA (1) ZA200103769B (pt)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
WO2002056132A2 (en) * 2000-11-01 2002-07-18 Snapnames Com Inc Domain name acquisition and management system and method
BR0209774A (pt) 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
HUP0402106A3 (en) 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
ES2294190T3 (es) 2001-11-01 2008-04-01 Janssen Pharmaceutica N.V. Derivados de amida como inhibidores de la glucogeno sintasa quinasa 3-beta.
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1504047B1 (en) * 2002-05-03 2007-12-12 Janssen Pharmaceutica N.V. Polymeric microemulsions
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
DK1529032T3 (da) * 2002-08-09 2013-07-08 Janssen Pharmaceutica Nv Fremgangsmåder til fremstilling af 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)aminobenzonitrill
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
HRP20050690A2 (en) * 2003-02-07 2006-08-31 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
ES2325440T3 (es) * 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ES2667668T3 (es) 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CN100475815C (zh) * 2003-09-25 2009-04-08 詹森药业有限公司 抑制hiv复制的嘌呤衍生物
CA2557790A1 (en) 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
US7923554B2 (en) 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
ES2371924T3 (es) 2004-09-30 2012-01-11 Tibotec Pharmaceuticals Pirimidinas 5-carbo o heterociclo- sustituidas que inhiben el hiv.
JP5046943B2 (ja) * 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性５−置換ピリミジン
WO2006035067A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
JP5118972B2 (ja) 2004-10-29 2013-01-16 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性二環式ピリミジン誘導体
WO2006052373A2 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
RU2403245C2 (ru) 2005-01-27 2010-11-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)пиримидина
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
ES2533258T3 (es) * 2005-02-18 2015-04-08 Janssen Sciences Ireland Uc Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH
ME01229B (me) 2005-03-04 2013-06-20 Janssen R& D Ireland 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
MX2007014881A (es) 2005-05-26 2008-02-15 Tibotec Pharm Ltd Procedimiento para preparar 4-(1,6-dihidro-6-oxo-2-pirimidinil) amino benzonitrilo.
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007044565A2 (en) * 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
CA2631876C (en) 2006-01-19 2014-05-27 Janssen Pharmaceutica N.V. Aminophenyl derivatives as inhibitors of histone deacetylase
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP1981875B1 (en) 2006-01-19 2014-04-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
ES2353725T3 (es) 2006-03-30 2011-03-04 Tibotec Pharmaceuticals Pirimidinas sustituidas con 5-(hidroximetileno y aminometileno) que inhiben el vih.
CN101405283B (zh) 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
HRP20110883T1 (hr) 2006-06-06 2012-01-31 Tibotec Pharmaceuticals Postupak za pripremanje raspršivanjem osušenih formulacija tmc125
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
WO2008068299A2 (en) 2006-12-06 2008-06-12 Tibotec Pharmaceuticals Ltd. Hydrobromide salt of an anti-hiv compound
AU2007341228B2 (en) * 2006-12-29 2013-04-18 Janssen Sciences Ireland Uc HIV inhibiting 5,6-substituted pyrimidines
AU2007341227C1 (en) 2006-12-29 2013-08-29 Janssen Sciences Ireland Uc HIV inhibiting 6-substituted pyrimidines
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
JP5748737B2 (ja) 2009-03-30 2015-07-15 ヤンセン・アールアンドデイ・アイルランド エトラビリンとニコチンアミドの共結晶
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
EP2342186B1 (en) * 2009-06-22 2014-09-17 Emcure Pharmaceuticals Limited Process for synthesis of etravirine
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
ES2577829T3 (es) 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
EP2584901A4 (en) 2010-06-28 2013-10-09 Hetero Research Foundation PROCESS FOR PREPARING THE INTERMEDIATE OF STRAIN AND STRAIN OF POLYMORPHS
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
NO2638031T3 (pt) 2010-11-10 2018-03-10
PL2702045T3 (pl) 2011-04-26 2018-04-30 Mylan Laboratories Ltd. Nowy sposób sporządzania Etrawiryny
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
PL2748166T3 (pl) 2011-08-23 2019-05-31 Asana Biosciences Llc Związki pirimido-pirydazynonowe oraz ich zastosowanie
US20130123498A1 (en) 2011-10-19 2013-05-16 Maja Sepelj MAJER Process for the preparation of etravirine and intermediates in the synthesis thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
BR112014022790B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
BR112015014836A2 (pt) 2012-12-21 2017-07-11 Verlyx Pharma Inc método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
CN118105392A (zh) 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
EP3994132A1 (en) 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
EP0172786B1 (de) * 1984-06-25 1991-01-30 Ciba-Geigy Ag Pyrimidinderivate wirksam als Schädlingsbekämpfungsmittel
WO1989009213A1 (fr) 1988-03-31 1989-10-05 Mitsubishi Kasei Corporation Derives de nucleoside de pyrimidine acyclique substitue en 6 et agents antiviraux contenant ces composes en tant qu'ingredients actifs
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
BR9611562A (pt) 1995-11-23 1999-03-02 Janssen Pharmaceutica Nv Misturas sólidas de ciclodextrinas preparadas via extrusão sob fusão
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
EA002973B1 (ru) * 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
EP0945442A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
AU782948B2 (en) * 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines

Also Published As

Publication number Publication date
AP1683A (en) 2006-11-29
NO318801B1 (no) 2005-05-09
AR024227A1 (es) 2002-09-25
US20050288278A1 (en) 2005-12-29
NO20011696D0 (no) 2001-04-04
LU91528I9 (pt) 2019-01-02
FR09C0004I2 (fr) 2010-06-11
JP3635238B2 (ja) 2005-04-06
TWI238161B (en) 2005-08-21
EP1002795A1 (en) 2000-05-24
SK6032001A3 (en) 2002-01-07
US7037917B2 (en) 2006-05-02
BR9915552B1 (pt) 2013-11-19
SK287269B6 (sk) 2010-05-07
NO2021015I1 (no) 2021-03-29
NL300373I2 (nl) 2009-04-01
OA11674A (en) 2005-01-12
CZ301367B6 (cs) 2010-02-03
DE69905683T2 (de) 2004-03-18
PL347586A1 (en) 2002-04-08
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
JP2002529456A (ja) 2002-09-10
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
CY2008021I2 (el) 2010-07-28
EA200100536A1 (ru) 2002-02-28
HUP0104177A3 (en) 2003-01-28
HRP20010161A2 (en) 2002-02-28
NL300373I1 (nl) 2009-03-02
HU227453B1 (en) 2011-06-28
HK1048817A1 (en) 2003-04-17
EE05086B1 (et) 2008-10-15
NZ511116A (en) 2003-08-29
PL204427B1 (pl) 2010-01-29
TR200101306T2 (tr) 2001-10-22
HRP20010161B1 (en) 2009-03-31
MY121108A (en) 2005-12-30
UA70966C2 (uk) 2004-11-15
US20040039005A1 (en) 2004-02-26
KR100658489B1 (ko) 2006-12-18
IL143023A0 (en) 2002-04-21
HU230394B1 (hu) 2016-04-28
US20080176880A1 (en) 2008-07-24
CZ20011533A3 (cs) 2001-10-17
WO2000027825A1 (en) 2000-05-18
SI1002795T1 (en) 2003-10-31
KR20010075235A (ko) 2001-08-09
EP1270560A1 (en) 2003-01-02
LU91528I2 (fr) 2009-04-20
BG65103B1 (bg) 2007-02-28
BG105418A (en) 2001-11-30
AU762523B2 (en) 2003-06-26
AU6200899A (en) 2000-05-29
CN1322198A (zh) 2001-11-14
EA004049B1 (ru) 2003-12-25
CA2350801A1 (en) 2000-05-18
CA2350801C (en) 2008-05-20
HRP20080359B1 (hr) 2016-01-01
HRP20010161B9 (hr) 2014-10-24
US8530655B2 (en) 2013-09-10
NO20011696L (no) 2001-04-04
CY2008021I1 (el) 2010-07-28
NO2009003I1 (no) 2009-03-09
US20110263625A1 (en) 2011-10-27
ATE233740T1 (de) 2003-03-15
ATE455107T1 (de) 2010-01-15
EP1270560B1 (en) 2010-01-13
AU2011200708A1 (en) 2011-03-10
DE122009000003I1 (de) 2009-05-20
ES2338760T3 (es) 2010-05-12
HRP20080359A2 (en) 2008-12-31
PT1002795E (pt) 2003-07-31
ES2193664T3 (es) 2003-11-01
US6878717B2 (en) 2005-04-12
NO2009003I2 (no) 2010-06-07
EE200100252A (et) 2002-10-15
FR09C0004I1 (pt) 2009-02-27
LTC1002795I2 (lt) 2021-06-10
LTPA2008016I1 (lt) 2021-04-26
IL169949A (en) 2011-02-28
HUP0104177A2 (hu) 2002-03-28
CN1214013C (zh) 2005-08-10
AU762523C (en) 2004-02-12
BR9915552A (pt) 2001-08-14
ZA200103769B (en) 2002-08-12
HK1025330A1 (en) 2000-11-10
EP1002795B1 (en) 2003-03-05
HK1048817B (en) 2010-04-09
US8003789B2 (en) 2011-08-23
DE69941934D1 (de) 2010-03-04

Similar Documents

Publication Publication Date Title
BRPI9915552B8 (pt) pirimidinas inibidoras da reprodução do hiv
AP1610A (en) HIV replication inhibiting pyrimidines.
MXPA05008364A (es) Derivados de pirimidina para la prevencion de una infeccion por vih.
AP1468A (en) Hiv inhibiting pyrimidine derivatives.
AP1475A (en) Trisubstituted 1, 3, 5-triazine derivatives for treatment of HIV infections.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EE05065B1 (et) Karbamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
MY138308A (en) Hiv replication inhibiting pyrimidines and triazines
CY1110979T1 (el) Παραγωγα κιναζολινης ως αναστολεις αγγειογενεσης και ενδιαμεσες ενωσεις αυτων
JPH11193282A5 (pt)
ATE375984T1 (de) Chinazolin derivate
DE60001586D1 (de) Diphenyl-piperidin derivate
ATE300178T1 (de) Herbizide wirkstoffkombinationen
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
ES2196332T3 (es) Derivados de hexahidro-pirido(4,3-b)indol como farmacos antipsicoticos.
YU39503A (sh) Derivati pirimidina
BR9915176A (pt) Derivados de triazina dissubstituìdos nas posições 2,4
ATE500231T1 (de) Hiv hemmende pyrimidin derivate
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
CY1125571T1 (el) Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv
UA81654C2 (ru) Пиримидины и триазины, которые ингибируют репликацию вич

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/09/2019